01—Abstract
Summary
Summary of the 8-K filed December 8, 2025. Cited figures are marked; the original filing is the authoritative source.
Viatris Inc. (Nasdaq: VTRS) has entered into definitive agreements with Biocon Limited to sell its equity stake in Biocon Biologics Limited, as announced in a December 6, 2025 press release (Exhibit 99.1) furnished under Item 7.01 of this Form 8-K.
Under the agreements, Biocon will acquire all of Viatris' convertible preferred equity in Biocon Biologics for total consideration of $815 milliona, consisting of $400 million in cash and $415 million in newly issued equity shares of Biocon Limited. The equity shares will be listed and traded on the National Stock Exchange of India and are subject to a six-month lock-up period. Transaction value will be subject to related taxes.
The transaction is expected to close in Q1 2026, subject to satisfaction of closing conditions. Viatris' CEO Scott A. Smith characterized the deal as another important step in the company's evolution, noting that monetizing the stake and regaining access to the global biosimilars market provides significant additional optionality for building a portfolio of generics, established brands and innovative brands.
The agreements also accelerate the expiration of biosimilars non-compete restrictions that were placed on Viatris in 2022 in connection with its sale of its biosimilars portfolio to Biocon Biologics. The restrictions will expire immediately at closing for all ex-U.S. markets and in November 2026 for U.S. markets.
02—Key points
Key Highlights
- Viatris will sell its convertible preferred equity in Biocon Biologics to Biocon for total consideration of $815 million.
- Consideration consists of $400 million in cash and $415 million in newly issued equity shares of Biocon Limited.
- The Biocon shares will be listed on the National Stock Exchange of India and are subject to a six-month lock-up period.
- Transaction value will be subject to related taxes.
- Biosimilars non-compete restrictions from 2022 expire immediately at closing for ex-U.S. markets and in November 2026 for U.S. markets.
- The transaction is expected to close in Q1 2026, subject to closing conditions.
- Citi is acting as financial advisor to Viatris; Cravath, Swaine & Moore LLP and Khaitan & Co. are legal advisors.
03—Questions
Frequently Asked Questions
What is the total value of the Biocon Biologics stake sale?
Viatris will receive total consideration of $815 million, made up of $400 million in cash and $415 million in newly issued equity shares of Biocon Limited.
When is the transaction expected to close?
The transaction is expected to close in Q1 2026, subject to satisfaction of closing conditions.
What restrictions does Viatris regain under this agreement?
The biosimilars non-compete restrictions placed on Viatris in 2022 will expire immediately at closing for all ex-U.S. markets and in November 2026 for U.S. markets, accelerating Viatris' access to the biosimilars market.
Are there any transfer restrictions on the Biocon shares Viatris will receive?
The Biocon equity shares are subject to a six-month lock-up period after they are issued.
Does the filing disclose the financial impact on Viatris' earnings?
The filing does not state an accounting gain, loss or earnings impact from the transaction; it describes the consideration, timing and restriction changes only.
04—Continue